Stockscreener 앱 받기
17.06
3.33%
0.55
시간 외 거래:
17.11
0.05
+0.29%
전일 마감가:
$16.51
열려 있는:
$16.53
하루 거래량:
415.88K
Relative Volume:
0.81
시가총액:
$4.66B
수익:
$1.40B
순이익/손실:
$164.00M
주가수익비율:
28.39
EPS:
0.6009
순현금흐름:
$-11.09M
1주 성능:
-1.10%
1개월 성능:
-5.17%
6개월 성능:
-17.82%
1년 성능:
-29.21%
1일 변동 폭
$16.50
$17.74
1주일 범위
$16.27
$17.74
52주 변동 폭
$12.89
$28.00
Stevanato Group Spa Stock (STVN) Company Profile
Compare STVN vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STVN
Stevanato Group Spa
|
17.06 | 4.54B | 1.40B | 164.00M | -11.09M | 0.6009 |
ISRG
Intuitive Surgical Inc
|
402.18 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
141.61 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.14 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.42 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
186.29 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Stevanato Group Spa Stock (STVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-12-13 | 개시 | Wolfe Research | Outperform |
| 2024-12-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-04-22 | 개시 | Exane BNP Paribas | Outperform |
| 2023-11-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-09-26 | 개시 | Stephens | Overweight |
| 2023-09-19 | 개시 | CJS Securities | Market Outperform |
| 2023-08-24 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-10 | 개시 | BofA Securities | Buy |
| 2021-08-10 | 개시 | Citigroup | Buy |
| 2021-08-10 | 개시 | Jefferies | Buy |
| 2021-08-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-08-10 | 개시 | Morgan Stanley | Overweight |
| 2021-08-10 | 개시 | Wells Fargo | Overweight |
모두보기
Stevanato Group Spa 주식(STVN)의 최신 뉴스
Stevanato Group S.p.A. (STVN) Stock Analysis: Exploring a 42.79% Potential Upside in the Medical Instruments Sector - DirectorsTalk Interviews
Stevanato Group (STVN) Stock Valuation Check After Recent Share Price Weakness - Yahoo Finance
Sustainable Pharmaceutical Packaging Market to Reach USD 270.4 Billion by 2031, Wissen Research - Moomoo
Is Stevanato Group S.p.A. (STVN) A Good Stock To Buy Now? - Insider Monkey
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside - Seeking Alpha
Stevanato Group launches pen injector for diabetes drugs By Investing.com - Investing.com Nigeria
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now - The Motley Fool
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies - Manufacturing Chemist
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneo - GuruFocus
Stevanato Group (STVN) Q1 2026 Earnings: EPS Beats Estimates Amid Quiet Revenue DisclosureShort-Term Outlook - newsline.com
Stevanato Group Launches Deora Pen Injector for Diabetes and Weight Management Therapies - World Business Outlook
Stevanato Group launches pen injector platform targeting GLP-1, obesity drug market - Medical Economics
Stevanato Group Introduces New Proprietary Pen Injector Platform - Contract Pharma
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management - Stevanato Group S.p.A. (STVN)
Stevanato Group launches pen injector for diabetes drugs - Investing.com UK
Stevanato Group S.p.A. (STVN): Analyst Consensus Highlights 32.12% Potential Upside - DirectorsTalk Interviews
Stevanato Group S.p.A (STVN) Q4 2023 Earnings Call Transcript - MLQ.ai
(STVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Stevanato Group (STVN) Holds Steady Near Support as Market Weighs FundamentalsBollinger Band - newsline.com
[6-K] Stevanato Group S.p.A. Current Report (Foreign Issuer) | STVN SEC FilingForm 6-K - Stock Titan
Stevanato faces earnings test on high-value product mix shift By Investing.com - Investing.com UK
Stevanato faces earnings test on high-value product mix shift - Investing.com
Stevanato Group’s Quiet Revolution: Governance for a Modern Era - BriefGlance
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting - Stevanato Group S.p.A. (STVN)
Implied Volatility Surging for Stevanato Stock Options - Yahoo Finance
STVN Assumes Outperform by Wolfe Research -- Price Target Announ - GuruFocus
Wolfe Research initiates Stevanato stock with Outperform rating By Investing.com - Investing.com India
Wolfe Research initiates Stevanato stock with Outperform rating - Investing.com
Stevanato Group S.p.A. (STVN) Stock Analysis: An Under-the-Radar Healthcare Gem with 33% Upside Potential - DirectorsTalk Interviews
Stevanato’s GLP-1 Tailwinds Meet A Guidance Reality Check - Finimize
Stevanato Group (STVN) Holds Steady Near $18.66 as Consolidation BuildsHigh Volume Node - newsline.com
Stevanato Group (STVN) Q1 2026 Earnings: EPS Beat Drives Shares Higher Despite Revenue UncertaintyEarnings Decline Risk - newsline.com
Stevanato Group SpA (N: STVN) Share Price, STVN Stock News, STVN Share Price & Updates - Kalkine
Stevanato Group (STVN) Edges Lower Amid Light Trading, Holds Near Key SupportVolume Spike Alerts - newsline.com
(STVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Stevanato Group S.p.A. (STVN) Stock Analysis: Unpacking a Potential 37.89% Upside in the Healthcare Sector - DirectorsTalk Interviews
Stevanato maintains 2026 guidance of €1.260B-€1.290B revenue as it targets RTU cartridge production in early 2027 - MSN
Stevanato Group's Valuation Adjustment Signals Improved Financial Health and Market Position - Markets Mojo
Top Stevanato Group (STVN) Competitors 2026 - MarketBeat
Stevanato Group Earnings Call Highlights Growth and Strain - The Globe and Mail
Stevanato Group Posts Strong Q1 2026 Growth and Accelerates Cartridge Capacity Expansion - TipRanks
Stevanato Group S.p.A. (STVN) Stock Analysis: A 38% Potential Upside Draws Investor Attention - DirectorsTalk Interviews
Liquidity Mapping Around (STVN) Price Events - Stock Traders Daily
Stevanato Group S.p.A. Ordinary Shares (NY: STVN - The Chronicle-Journal
Stevanato Group (NYSE: STVN) posts Q1 2026 growth and reaffirms 2026 outlook - Stock Titan
Baron entities (STVN) report 2.5M shares, 5.03% beneficial ownership - Stock Titan
Stevanato Group Spa (STVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.23%
자본화:
|
볼륨(24시간):